{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:48:12Z","timestamp":1788875292824,"version":"build-2803163510"},"reference-count":59,"publisher":"Wiley","issue":"S3","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>After decades of stumbling clinical development, the first gene therapies for haemophilia A and B have been commercialized and have normalized factor (F)VIII and factor (F)IX levels in some individuals in the long term. Several other clinical programs testing adeno\u2010associated viral (AAV) vector gene therapy are at various stages of clinical testing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Multiyear follow\u2010up in phase 1\/2 and 3 studies showed long\u2010term and sometimes curative but widely variable and unpredictable efficacy. Liver toxicities, mostly low\u2010grade, occur in the 1st year in at least some individuals in all haemophilia A and B trials and are poorly understood. Wide variability and unpredictability of outcome and slow decline of FVIII levels are a major disadvantage because immune responses to AAV vectors preclude repeat dosing, which otherwise could improve suboptimal or restore declining expression, while overexpression may predispose to thrombosis. Long\u2010term safety outcomes will need lifelong monitoring because AAV vectors infused at high doses integrate into chromosomes at rates that raise questions about potential oncogenicity and necessitate vigilance. Alternative gene transfer systems employing gene editing and\/or non\u2010viral vectors are under development and promise to overcome some limitations of the current state of the art for both haemophilia A and B.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>AAV gene therapies for haemophilia have now become new treatment options but not universal cures. AAV is a powerful but imperfect gene transfer platform. Biobetter FVIII transgenes may help solve some problems plaguing gene therapy for haemophilia A. Addressing variability and unpredictability of efficacy, and delivery of gene therapy to ineligible patient subgroups may require different gene transfer systems, most of which are not ready for clinical translation yet but bring innovations needed to overcome the current limitations of gene therapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14984","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T05:05:21Z","timestamp":1711429521000},"page":"12-20","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Current and emerging gene therapies for haemophilia A and B"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8084-1958","authenticated-orcid":false,"given":"Radoslaw","family":"Kaczmarek","sequence":"first","affiliation":[{"name":"Wells Centre for Paediatric Research Indiana University School of Medicine  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4506-0061","authenticated-orcid":false,"given":"Wolfgang","family":"Miesbach","sequence":"additional","affiliation":[{"name":"Department of Haemostasis\/Haemophilia Centre Laboratory for Coagulation Disorders University Hospital Frankfurt  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5938-0675","authenticated-orcid":false,"given":"Margareth C.","family":"Ozelo","sequence":"additional","affiliation":[{"name":"Hemocentro UNICAMP Department of Internal Medicine School of Medical Sciences University of Campinas  Campinas SP Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6690-8586","authenticated-orcid":false,"given":"Pratima","family":"Chowdary","sequence":"additional","affiliation":[{"name":"Katharine Dormandy Haemophilia and Thrombosis Centre Royal Free Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/299178a0"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/312342a0"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.09.020"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.12.001"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14530"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.03.001"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.12.005"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106073442301"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0167"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3296"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1358"},{"key":"e_1_2_7_13_1","volume-title":"Hemostatic results for up to 6 years following treatment with valoctocogene roxaparvovec, an AAV5\u2010hFVIII\u2010SQ gene therapy for severe hemophilia A","author":"Laffan M","year":"2022"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708483"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005683"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113708"},{"key":"e_1_2_7_17_1","doi-asserted-by":"crossref","unstructured":"MahlanguJ vonDrygalskiA ShapiroS et\u00a0al.Bleeding FVIII activity and safety 3 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8\u20101.OC 201 ISTH 2023.2023.","DOI":"10.1016\/j.rpth.2023.100459"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211075"},{"key":"e_1_2_7_19_1","article-title":"Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104\u2010week analysis of the Phase 1\/2 Alta study","author":"Leavitt AD","year":"2023","journal-title":"Blood Journal"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104205"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.2174\/1566523222666220914105729"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159363"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180803"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.221093"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108046"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186891"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-804419"},{"key":"e_1_2_7_28_1","volume-title":"Five Year Data Confirms Stable FIX Expression and Sustained Reductions in Bleeding and Factor IX Use Following AMT\u2010060 Gene Therapy in Adults with Severe or Moderate\u2010severe Hemophilia B \u2010","author":"Miesbach W","year":"2021"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904377"},{"key":"e_1_2_7_30_1","volume-title":"Results from BeneGene\u20101 Study: prospective Collection of Bleeding Rate in hemophilia B Patients Prior to Phase 3 Study (BeneGene\u20102) of Fidanacogene Elaparvovec","author":"Matino D","year":"2023"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150541"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119913"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008886"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211644"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187624"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.06.016"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13972"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14015"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15023"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.12.039"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.23.14793-14803.2005"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.10.022"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.06.004"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.10.024"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004625"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009876"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2268279"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.10.005"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2014.36"},{"key":"e_1_2_7_50_1","unstructured":"ASC Therapeutics Doses First Patient with ASC618 Second\u2010Generation Gene Therapy for Hemophilia A | Business Wire."},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188513"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-172845"},{"key":"e_1_2_7_53_1","unstructured":"Magenta Therapeutics Voluntarily Pauses the MGTA\u2010117 Phase."},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182468"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.10.010"},{"key":"e_1_2_7_56_1","unstructured":"HuangH Moroski\u2010ErkulC BialekP et\u00a0al.CRISPR\/Cas9\u2010Mediated Targeted Insertion of Human F9 Achieves Therapeutic Circulating Protein Levels in Mice and Non\u2010Human Primates. In:22nd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).Washington DC:Academic Press;2019."},{"key":"e_1_2_7_57_1","unstructured":"SabinL Novel Approaches for Gene\u2010Based Therapies:\u200bTargeted Gene Insertion of Factor 9 as a Potential Durable Treatment for Hemophilia B. December2023."},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56123-5"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-189784"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26830-7"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14984","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T07:05:37Z","timestamp":1713683137000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":59,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/hae.14984"],"URL":"https:\/\/doi.org\/10.1111\/hae.14984","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]},"assertion":[{"value":"2024-01-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}